Information  X 
Enter a valid email address

C4X Discovery (C4XD)

  Print   

Tuesday 08 December, 2020

C4X Discovery

Clive Dix named Interim Chair of Vaccine Taskforce

RNS Number : 8334H
C4X Discovery Holdings PLC
08 December 2020
 

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

C4XD's Clive Dix steps up as Interim Chair of UK Vaccine Taskforce

 

Temporary role to ensure continuity at a critical time for the UK Vaccines programme

C4XD continues to make significant headway across portfolio

 

8 December 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, confirms that Clive Dix, Chief Executive Officer of C4XD has stepped into the role of Interim Chair of the UK Vaccine Taskforce, the group set up by the Government to lead UK efforts to find and manufacture a COVID-19 vaccine.  The Government will set out arrangements for the long-term leadership of the Vaccine Taskforce shortly.

 

Clive is delivering on C4XD's strategy to advance its portfolio and this appointment will not impact his day-to-day role as CEO.

 

Eva-Lotta Allan, Chairman of C4XD, commented: "The Taskforce has worked tirelessly to seek and secure new vaccines for COVID-19.  This important work has resulted in the UK being at the forefront of both receiving and developing these critical vaccines and demonstrates the expertise and drive of all those involved.  As Kate Bingham has reached the end of her agreed tenure as Chair, to ensure the smooth continuity of the work carried out by the Taskforce, Clive is stepping into the role as Chair for an interim period. The Government will confirm longer-term arrangements for the Chair role soon.

 

"Clive continues to deliver strong leadership at C4XD with a recent fundraise of £15 million which has provided a strong foundation to continue driving focused progress across our core portfolio.  We look forward to providing a more in-depth update at our preliminary results later this month." 

 

Dr Clive Dix, CEO of C4X Discovery, said: "I am pleased to have had the opportunity thus far to contribute to the UK's fight against COVID-19 and believe that this transition is crucial to ensure continuity at this critical time.  I remain fully committed to our work at C4XD and will continue to drive progress across the portfolio alongside our strong management team and Board."

 

- Ends -

 

Contacts

 

C4X Discovery Holdings


Mo Noonan, Communications

+44 (0)787 6444977



Panmure Gordon (UK) Limited (NOMAD and Broker)


Freddy Crossley, Emma Earl (Corporate Finance)

+44 (0)20 7886 2500

Rupert Dearden (Corporate Broking)




C4X Discovery Media - Consilium Strategic Communications


Mary-Jane Elliott, Chris Gardner, Matthew Neal

+44 (0)203 709 5700

 

 

Notes to Editors:

 

About the UK Vaccine Taskforce

The Taskforce is supporting efforts to develop a COVID-19 vaccine as soon as possible by providing industry and research institutions with the resources and support needed. This includes working with regulators and scaling up manufacturing, so that when a vaccine is identified, it can be produced quickly and at scale.

 

The Bioindustry Association is working closely with the Taskforce, bringing together a whole range of businesses keen to use their expertise to mass-produce vaccines, as soon as one is ready.

 

About C4X Discovery

C4X Discovery (C4XD) aims to create the world's most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m, which is now in a Phase I clinical study.

 

C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD's commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.

 

For additional information please go to: www.c4xdiscovery.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFSIFWWESSEIE

a d v e r t i s e m e n t